Literature DB >> 7806174

Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: cholesterol absorption and synthesis related to lipoprotein levels and their kinetics.

H Gylling1, M Färkkilä, M Vuoristo, T A Miettinen.   

Abstract

Cholesterol absorption, elimination, and synthesis, and low-density lipoprotein (LDL) and high density lipoprotein (HDL) kinetics were studied in patients with mild to severe primary biliary cirrhosis (PBC) (n = 16) to show how this cholestatic disease modified cholesterol and lipoprotein metabolism as compared with healthy controls (n = 50). Serum total and lipoprotein cholesterol and triglyceride levels were similar in the two groups, but in PBC, especially in severe forms, very low density lipoprotein (VLDL) was rich in apoprotein (apo) B and cholesterol and low in triglycerides, whereas LDL was rich in triglycerides and low in esterified cholesterol, and HDL was enriched by surface lipids, phospholipids, and free cholesterol. In severe PBC, the fractional catabolic rate (FCR) for LDL apo B was reduced. The transport rate (TR) for LDL apo B was unaffected and it tended to correlate with the LDL apo B and LDL cholesterol levels in PBC, whereas in the controls the LDL apo B concentration was regulated by both the FCR and TR, and LDL cholesterol was regulated only by FCR. FCR for apo A-I in HDL was unaltered in PBC, but TR for apo A-I was reduced in the severe cases. Cholesterol absorption efficiency was significantly reduced in PBC (14.5 +/- 3.0% in severe PBC and 34.0 +/- 2.5% in mild PBC vs. 47.4 +/- 1.4% in the controls, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7806174

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

Review 1.  Abnormalities of Lipoprotein Levels in Liver Cirrhosis: Clinical Relevance.

Authors:  Graziella Privitera; Luisa Spadaro; Simona Marchisello; Giuseppe Fede; Francesco Purrello
Journal:  Dig Dis Sci       Date:  2017-11-25       Impact factor: 3.199

2.  Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease.

Authors:  Iliana Doycheva; Chaoru Chen; Jen-Jung Pan; Cynthia Levy
Journal:  World J Hepatol       Date:  2011-04-27

3.  Acute coronary syndrome after liver transplantation in a young primary biliary cholangitis recipient with dyslipidemia: a case report.

Authors:  Siyuan Yao; Akiho Iwashita; Shintaro Yagi; Hirotoshi Watanabe; Takahiro Nishio; Yukinori Koyama; Kazuyuki Nagai; Naoko Kamo; Kojiro Taura; Etsuro Hatano
Journal:  Surg Case Rep       Date:  2022-06-17

Review 4.  Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications.

Authors:  Katriina Nemes; Fredrik Åberg; Helena Gylling; Helena Isoniemi
Journal:  World J Hepatol       Date:  2016-08-08

5.  Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis.

Authors:  M Longo; A Crosignani; P M Battezzati; C Squarcia Giussani; P Invernizzi; M Zuin; M Podda
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

Review 6.  Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy.

Authors:  Martin I Wah-Suarez; Christopher J Danford; Vilas R Patwardhan; Z Gordon Jiang; Alan Bonder
Journal:  Frontline Gastroenterol       Date:  2019-01-09

7.  Rosiglitazone alleviates intrahepatic cholestasis induced by α-naphthylisothiocyanate in mice: The role of circulating 15-deoxy-Δ12,14 -PGJ2 and Nogo.

Authors:  Shuang Zhang; Miao Yu; Fangling Guo; Xiaoxiao Yang; Yuanli Chen; Chuanrui Ma; Qi Li; Zhuo Wei; Xiaoju Li; Hua Wang; Huaqing Hu; Yujue Zhang; Derun Kong; Qing Robert Miao; Wenquan Hu; David P Hajjar; Yan Zhu; Jihong Han; Yajun Duan
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

Review 8.  Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).

Authors:  Jochen Mattner
Journal:  Int J Mol Sci       Date:  2016-11-09       Impact factor: 5.923

9.  Risk of Cardiovascular Events in Patients with Primary Biliary Cholangitis - Systematic Review.

Authors:  Duminda Suraweera; Christina Fanous; Melissa Jimenez; Myron J Tong; Sammy Saab
Journal:  J Clin Transl Hepatol       Date:  2018-02-14

Review 10.  Protective role of melatonin in early-stage and end-stage liver cirrhosis.

Authors:  Chenxia Hu; Lingfei Zhao; Jingjing Tao; Lanjuan Li
Journal:  J Cell Mol Med       Date:  2019-09-02       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.